Other languages Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
38.6 ^TWD	-9.92%		-10.23%	-40.71%

03-14	Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-06	Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	02-06
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO	02-06
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer	01-05
Tanvex BioPharma, Inc. Announces Change of Chairman	12-29
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023	12-21
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer	12-21
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023	12-21
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023	12-21
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer	11-30
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-12
Tanvex BioPharma, Inc. Announces Management Changes	11-01
Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08
Tanvex BioPharma, Inc. Appoints Peter K.H. Lin as Agent in Charge of Accounting Officer	23-03-03
Tanvex BioPharma, Inc. Announces Position Adjustment of Accounting Officer from Peter K.H. Lin to Ken Huang	23-02-20
Tanvex Biopharma, Inc. Announces Position Adjustment of Acting Spokesperson and Corporate Governance Officer from Jerry Yu to Stacey Tsai	23-02-20
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

Other languages

Filters